Nuklearmedizinische Klinik, Technischen Universität München, Munich, Germany.
J Nucl Med. 2012 Feb;53(2):318-23. doi: 10.2967/jnumed.111.091652.
(18)F-galacto-RGD ((18)F-RGD) is a PET tracer binding to α(v)β(3) integrin receptors that are upregulated after myocardial infarction (MI) as part of the healing process. We studied whether myocardial (18)F-RGD uptake early after MI is associated with long-term left-ventricle (LV) remodeling in a rat model.
Wistar rats underwent sham operation (n = 9) or permanent coronary ligation (n = 25). One week after MI, rats were injected with (18)F-RGD to evaluate α(v)β(3) integrin expression using a preclinical PET system. In the same rats, LV volumes and defect size were measured 1 and 12 wk after MI by (13)N-ammonia PET and MRI, respectively.
One week after MI, (18)F-RGD uptake was increased in the defect area as compared with the remote myocardium of MI rats or sham-operated controls (percentage injected dose per cubic centimeter, 0.20 ± 0.05 vs. 0.06 ± 0.03 and 0.07 ± 0.04, P < 0.001). At this time, (18)F-RGD uptake was associated with capillary density in histologic sections. Average (18)F-RGD uptake in the defect area was lowest in the rats demonstrating greater than 20% relative increase in the LV end-diastolic volume from 1 to 12 wk (percentage injected dose per centimeter cubed, 0.15 ± 0.07 vs. 0.21 ± 0.05, P < 0.05). In a multivariable logistic regression analysis, low (18)F-RGD uptake was a significant predictor of increase in end-diastolic volume (r = 0.51, P < 0.05).
High levels of (18)F-RGD uptake in the perfusion defect area early after MI were associated with the absence of significant LV remodeling after 12 wk of follow-up. These results suggest that α(v)β(3) integrin expression is a potential biomarker of myocardial repair processes after MI and enables the monitoring of these processes by molecular imaging to derive possible prognostic information.
(18)F-半乳糖-RGD((18)F-RGD)是一种与整合素 α(v)β(3)结合的 PET 示踪剂,在心肌梗死后(MI)作为愈合过程的一部分,该受体上调。我们研究了 MI 后早期心肌摄取(18)F-RGD 是否与大鼠模型中左心室(LV)重构的长期变化有关。
Wistar 大鼠接受假手术(n = 9)或永久性冠状动脉结扎(n = 25)。MI 后 1 周,大鼠注射(18)F-RGD,使用临床前 PET 系统评估 α(v)β(3)整合素表达。在相同的大鼠中,通过(13)N-氨 PET 和 MRI 分别在 MI 后 1 周和 12 周测量 LV 容积和缺陷大小。
MI 后 1 周,与 MI 大鼠或假手术对照组的远程心肌相比,(18)F-RGD 在缺陷区域的摄取增加(每立方厘米注射剂量的百分比,0.20 ± 0.05 与 0.06 ± 0.03 和 0.07 ± 0.04,P < 0.001)。此时,(18)F-RGD 的摄取与组织学切片中的毛细血管密度相关。从 1 周到 12 周,LV 舒张末期容积相对增加大于 20%的大鼠中,(18)F-RGD 在缺陷区域的摄取最低(每立方厘米厘米注射剂量的百分比,0.15 ± 0.07 与 0.21 ± 0.05,P < 0.05)。在多变量逻辑回归分析中,低(18)F-RGD 摄取是舒张末期容积增加的显著预测因子(r = 0.51,P < 0.05)。
MI 后早期灌注缺陷区域高摄取(18)F-RGD 与 12 周随访后无明显 LV 重构相关。这些结果表明,整合素 α(v)β(3)表达是 MI 后心肌修复过程的潜在生物标志物,并能通过分子成像监测这些过程,从而获得可能的预后信息。